Olanzapine‐induced weight gain and lipid dysfunction in mice between different gender

Abstract

As one of the most common antipsychotics, olanzapine may cause metabolic‐related adverse effects, but it is still unknown how olanzapine alters lipid metabolism. In this study, we found that olanzapine‐treated mice showed varying degrees of dyslipidemia, which was particularly pronounced in female mice. Based on ultra‐performance liquid chromatography–quadrupole time‐of‐flight–MS (UPLC–Q‐TOF–MS) technology and lipid metabolomics, we mapped the changes in lipid metabolism in olanzapine‐treated mice and then compared the changes in lipid metabolism between male and female mice. There were 98 metabolic differentiators between the olanzapine‐treated and control groups in females and 79 in males. These metabolites were glycerolipids, glycerophospholipids, fatty amides, and sphingolipids, which are involved in glycerolipid metabolism, glycerophospholipid metabolism, and fatty acid metabolism. These results suggest that olanzapine‐induced changes in the levels of lipid metabolites are closely associated with disturbances in lipid metabolic pathways, which may underlie lipemia. This lipidome profiling study not only visualizes changes in lipid metabolism in liver tissue but also provides a foundation for understanding the regulatory pathways and mechanisms involved in olanzapine‐induced lipid metabolism disorders. Furthermore, this study demonstrates differences in lipid metabolism between males and females, providing a reference for clinical treatment regimen selection.